Screener
Corvus Pharmaceuticals CRVS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $40,102 | $4,576 |
| Marketable securities | 196,612 | 52,174 |
| Accounts receivable - related party | 43 | 37 |
| Prepaid and other current assets | 3,189 | 1,427 |
| Total current assets | 239,946 | 58,214 |
| Property and equipment, net | 282 | 220 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's cash & equivalents?
- Corvus Pharmaceuticals (CRVS) reported cash & equivalents of $40.1M in Q1 2026.
- How has Corvus Pharmaceuticals's cash & equivalents changed year-over-year?
- Corvus Pharmaceuticals's cash & equivalents increased by 702.2% year-over-year, from $5M to $40.1M.
- What is the long-term trend for Corvus Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's cash & equivalents has grown at a -22.6% compound annual growth rate (CAGR), from $16.46M to $4.58M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Corvus Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude